Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Mark R, Trusheim"'
Publikováno v:
Drug Discovery Today. 27:17-30
Durable cell and gene therapies potentially transform patient lives, but payers fear unsustainable costs arising from the more than 1000 therapies in the development pipeline. A novel multi-module Markov chain Monte Carlo-based model projects product
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41142ffc28dcec03ba568855a512cf38
https://doi.org/10.1016/j.drudis.2021.09.001
https://doi.org/10.1016/j.drudis.2021.09.001
Autor:
Zeid El-Kilani, Jacqueline L. Chen, Ernst R. Berndt, Mark R. Trusheim, Ariel Dora Stern, Amber Jessup, Melissa Ouellet
Publikováno v:
Health Affairs. 40:989-999
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the US and worldwide. Against this backdrop, many look to the expanding market for biosimilars—foll...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::762d1a5bf84b209edbe679327ee5b57d
https://doi.org/10.1377/hlthaff.2020.02239
https://doi.org/10.1377/hlthaff.2020.02239
Publikováno v:
New England Journal of Medicine. 382:473-480
Rewards of Successful Drug Development Risks and rewards change during the life cycle of a drug. In the innovation period, drug companies invest in developing new products but cannot sell them. New...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d8271c65acf8f45cf06bb69484d4a47
https://doi.org/10.1056/nejmhpr1911004
https://doi.org/10.1056/nejmhpr1911004
Autor:
Ariel D, Stern, Mark R, Trusheim
Publikováno v:
Health affairs (Project Hope). 40(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5adcb433b8cc6c4a4fa1a8c3715c0b79
https://pubmed.ncbi.nlm.nih.gov/34495721
https://pubmed.ncbi.nlm.nih.gov/34495721
Autor:
Ariel Dora, Stern, Jacqueline L, Chen, Melissa, Ouellet, Mark R, Trusheim, Zeid, El-Kilani, Amber, Jessup, Ernst R, Berndt
Publikováno v:
Health affairs (Project Hope). 40(6)
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the US and worldwide. Against this backdrop, many look to the expanding market for biosimilars-follow-on products to biologic drugs-as a vehicle for con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2cdca55c2cb088169d9b8692dee3e7a1
https://pubmed.ncbi.nlm.nih.gov/34097520
https://pubmed.ncbi.nlm.nih.gov/34097520
Autor:
Kenneth A. Oye, Kenneth I. Kaitin, Newell E. McElwee, Heather C. Kaplan, Ralph B. D'Agostino, Richard L. Kravitz, Kay Larholt, Hans Georg Eichler, Willard H. Dere, Chandra Ramanathan, S. Nassir Ghaemi, Mark R. Trusheim, Eleanor M. Perfetto, Vicki L. Seyfert-Margolis, Marisha E. Palm, Theodora Cohen, Christopher H. Schmid, Peter Honig, Harry P. Selker
Publikováno v:
Clinical pharmacology and therapeutics. 112(2)
Clinicians and patients often try a treatment for an initial period to inform longer-term therapeutic decisions. A more rigorous approach involves N-of-1 trials. In these single-patient crossover trials, typically conducted in patients with chronic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1354af192cccc8bd0743b15002a21ff5
https://pubmed.ncbi.nlm.nih.gov/34551122
https://pubmed.ncbi.nlm.nih.gov/34551122
Autor:
David Strutton, Kay Larholt, Brigitte Schwarzer-Daum, Martin Brunninger, Gigi Hirsch, Markus Zeitlinger, Mark R. Trusheim, Hans-Georg Eichler, Michael Y. Sherman
Publikováno v:
Clinical pharmacology and therapeutics. 111(1)
Basic scientists and drug developers are accelerating innovations toward the goal of precision medicine. Regulators create pathways for timely patient access to precision medicines, including individualized therapies. Healthcare payors acknowledge th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebdb104bd513c835061a8aadf69204e9
https://pubmed.ncbi.nlm.nih.gov/34716918
https://pubmed.ncbi.nlm.nih.gov/34716918
Autor:
Mondher Toumi, Hilde Stevens, Sissel Michelsen, Isabelle Huys, Eline van Overbeeke, Steven Simoens, Mark R. Trusheim
Publikováno v:
Drug discovery today
This review can inform gene therapy developers on challenges that can be encountered when seeking market access. Moreover, it provides an overview of trends among challenges and potential solutions.
SCOPUS: re.j
info:eu-repo/semantics/publi
SCOPUS: re.j
info:eu-repo/semantics/publi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be478b77e04ec11c937d6126c3db20eb
https://pubmed.ncbi.nlm.nih.gov/33242695
https://pubmed.ncbi.nlm.nih.gov/33242695
Publikováno v:
International Journal of Technology Assessment in Health Care. 34:163-171
Objectives: Value assessment frameworks have gained prominence recently in the context of U.S. healthcare. Such frameworks set out a series of factors that are considered in funding decisions. The UK's National Institute of Health and Care Excellence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e747888b8415705aa5445afbbbb908
https://doi.org/10.1017/s0266462318000090
https://doi.org/10.1017/s0266462318000090
Autor:
Mark R. Trusheim, Ariel Dora Stern
Publikováno v:
Health Affairs. 40:1516-1516
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce71d937cb51c7241af3882376e14067
https://doi.org/10.1377/hlthaff.2021.01179
https://doi.org/10.1377/hlthaff.2021.01179